Topline Findings
- Novo Nordisk Layoffs: The company announced a global workforce reduction of 9,000 positions, including 5,000 in Denmark, as part of a strategic restructuring to focus on diabetes and obesity growth areas.
- Financial Impact: The restructuring is expected to generate $1.25 billion in annual savings by 2026 while incurring $1.26 billion in one-off costs, prompting a revision of 2025 operating profit growth to 4%–10% at constant exchange rates.
- Industry Context: Novo Nordisk’s layoffs reflect a broader pharmaceutical trend in 2025, with major companies including Bayer, Merck, Moderna, Pfizer, CSL, Fate Therapeutics, Generation Bio, Lundbeck, and ORIC Pharmaceuticals also reducing staff to streamline operations and improve efficiency.
Novo Nordisk has announced a massive round of layoffs as part of a major restructuring effort aimed at simplifying its organization, accelerating decision-making, and redirecting resources to its core growth areas of diabetes and obesity.
The plan includes reducing about 9,000 positions globally—5,000 of which are in Denmark—out of its 78,400 employees. According to the company, the layoffs are intended to streamline operations, reduce complexity, and free up resources to reinvest in diabetes and obesity therapies, for which demand and competition are rapidly increasing.1
How will Novo Nordisk’s Restructuring Impact its Strategic Priorities?
“As the global leader in obesity and diabetes, Novo Nordisk delivers life-changing products for patients worldwide,” said Mike Doustdar, CEO, president, Novo Nordisk, in a press release. “But our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven.”
Financial Impact of the Restructuring
The layoffs are expected to generate approximately $1.25 billion in annual savings by 2026, which the company expects to reinvest in commercial execution, R&D, and manufacturing scale-up. Additionally, the restructuring is expected to bring an estimated $1.26 billion in net one-off costs, including impairments, with about $1.41 billion incurred in Q3 2025 and $157 million in offsetting savings in Q4.
As a result, the company has lowered its 2025 operating profit growth forecast at constant exchange rates to 4%–10%, down from 10%–16% previously. Despite the near-term hit, Novo Nordisk sees the layoffs as essential to positioning the company for sustainable long-term growth and innovation in its leading therapeutic areas.1
Market Pressures Behind the Layoffs
These job cuts were announced as competition becomes fiercer in the fast-growing obesity treatment market. Last month, Novo Nordisk announced that it was implementing a hiring freeze for all non-business-critical areas.
While the company didn’t offer a reason behind the hiring freeze, analysts noted that competition from Eli Lilly’s Zepbound and the company’s stock recently falling to a three-year low may have contributed. This represented one of the company’s largest single-day stock declines in decades.2
